Mustang Bio to Initiate P-I Clinical Trial for MB-101 + MB-108 for the Treatment of Glioblastoma
Shots:
- The company plans to initiate a P-I study to evaluate MB-108 + MB-101 in patients with rGBM. The study was supported by the data collected from two ongoing P-I trials for MB-108 & MB-101 individually
- The P-I study of MB-101 demonstrated infusions were well tolerated with clinically manageable flu-like symptoms & provides possible survival benefit vs historical control. The results of the MB108 trial study demonstrated T cell immune recruitment differences compared to the untreated region
- Based on the preclinical data presented at AACR 2022, the therapy was found to be safe to administer consecutively as MB-109, showing no AEs & tumor shrinkage at low doses
Ref: Globe Newswire| Image: Mustang Bio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
